ovalbumin and Acquired-Immunodeficiency-Syndrome

ovalbumin has been researched along with Acquired-Immunodeficiency-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for ovalbumin and Acquired-Immunodeficiency-Syndrome

Article	Year
GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses. Vaccine, 2011, Apr-27, Volume: 29, Issue:19 The limitations of highly active anti-retroviral therapy (HAART) have necessitated the development of alternative therapeutics. In this study, we generated ovalbumin (OVA)-pulsed and pcDNAgp120-transfected dendritic cell (DC)-released exosomes (EXOova and EXOgp120) and ConA-stimulated C57BL/6 CD8(+) T cells. OVA- and Gp120-Texo vaccines were generated from CD8(+) T cells with uptake of EXOova and EXOgp120, respectively. We demonstrate that OVA-Texo stimulates in vitro and in vivo OVA-specific CD4(+) and CD8(+) cytotoxic T lymphocyte (CTL) responses leading to long-term immunity against OVA-expressing BL6-10(OVA) melanoma. Interestingly, CD8(+) T cell responses are DC and CD4(+) T cell independent. Importantly, Gp120-Texo also stimulates Gp120-specific CTL responses and long-term immunity against Gp120-expressing B16 melanoma. Therefore, this novel HIV-1-specific EXO-targeted Gp120-Texo vaccine may be useful in induction of efficient CTL responses in AIDS patients with DC dysfunction and CD4(+) T cell deficiency. Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Animals; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Dendritic Cells; Exosomes; Female; HIV Envelope Protein gp120; HIV-1; Immunity, Cellular; Immunologic Memory; Intercellular Adhesion Molecule-1; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin	2011
CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients. Proceedings of the National Academy of Sciences of the United States of America, 1991, Jul-01, Volume: 88, Issue:13 Sera from human immunodeficiency virus-positive (HIV+; Walter Reed stage 6) individuals inhibit the interaction between recombinant human CD4 and recombinant gp120 from HIV (rCD4 and rgp120, respectively), thereby interfering with the ability of soluble rCD4 to block infection with HIV or rCD4-toxin conjugates to kill HIV-infected cells. In this report we demonstrate that the inhibitory activity of such sera is caused primarily by anti-gp120 antibodies that do not recognize the CD4 interaction site on gp120. To circumvent the problem of inhibition, we have generated a construct containing a peptide of CD4 (residues 41-84) conjugated to ovalbumin (three to five peptides per molecule). This multivalent conjugate binds to rgp120 and binding is not inhibited by antibodies in HIV+ sera. Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Antibody Specificity; CD4 Antigens; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; In Vitro Techniques; Molecular Sequence Data; Ovalbumin; Peptides; Recombinant Proteins	1991

Article

Year

GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.

Vaccine, 2011, Apr-27, Volume: 29, Issue:19

The limitations of highly active anti-retroviral therapy (HAART) have necessitated the development of alternative therapeutics. In this study, we generated ovalbumin (OVA)-pulsed and pcDNAgp120-transfected dendritic cell (DC)-released exosomes (EXOova and EXOgp120) and ConA-stimulated C57BL/6 CD8(+) T cells. OVA- and Gp120-Texo vaccines were generated from CD8(+) T cells with uptake of EXOova and EXOgp120, respectively. We demonstrate that OVA-Texo stimulates in vitro and in vivo OVA-specific CD4(+) and CD8(+) cytotoxic T lymphocyte (CTL) responses leading to long-term immunity against OVA-expressing BL6-10(OVA) melanoma. Interestingly, CD8(+) T cell responses are DC and CD4(+) T cell independent. Importantly, Gp120-Texo also stimulates Gp120-specific CTL responses and long-term immunity against Gp120-expressing B16 melanoma. Therefore, this novel HIV-1-specific EXO-targeted Gp120-Texo vaccine may be useful in induction of efficient CTL responses in AIDS patients with DC dysfunction and CD4(+) T cell deficiency.

Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Animals; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Dendritic Cells; Exosomes; Female; HIV Envelope Protein gp120; HIV-1; Immunity, Cellular; Immunologic Memory; Intercellular Adhesion Molecule-1; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin

2011

CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.

Proceedings of the National Academy of Sciences of the United States of America, 1991, Jul-01, Volume: 88, Issue:13

Sera from human immunodeficiency virus-positive (HIV+; Walter Reed stage 6) individuals inhibit the interaction between recombinant human CD4 and recombinant gp120 from HIV (rCD4 and rgp120, respectively), thereby interfering with the ability of soluble rCD4 to block infection with HIV or rCD4-toxin conjugates to kill HIV-infected cells. In this report we demonstrate that the inhibitory activity of such sera is caused primarily by anti-gp120 antibodies that do not recognize the CD4 interaction site on gp120. To circumvent the problem of inhibition, we have generated a construct containing a peptide of CD4 (residues 41-84) conjugated to ovalbumin (three to five peptides per molecule). This multivalent conjugate binds to rgp120 and binding is not inhibited by antibodies in HIV+ sera.

Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Antibody Specificity; CD4 Antigens; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; In Vitro Techniques; Molecular Sequence Data; Ovalbumin; Peptides; Recombinant Proteins

1991